Amorphous solid dispersions can overcome bioavailability issues with oral oncology drugs.

Demonstrating Enhanced Capabilities of ASD Tablets

Topic

Articles

Spectrum Chemical scientists give a shout-out to 10 chemicals impacting quality of life in conjunction with National Chemistry Week.

Spectrum Chemical Names Top 10 Chemicals Impacting Quality of Life

Crystec and Biosidus have joined forces to enhance the delivery and performance of biotherapeutics.

Crystec, Biosidus Collaborate on Enhanced Delivery and Performance of Biotherapeutics 

Ferrer and Treeway, have entered into a license agreement for the development and commercialization of an oral formulation of edaravone (TW001/FNP122).

Ferrer, Treeway Partner on Development and Commercialization of ALS Treatment

Andrew Mansfield is flow chemistry leader at Syrris.

The ever-increasing interest in photochemistry has inspired the development of innovative, modular flow photochemistry reactors.

Shining a Light on Photochemistry in Flow

In this collaboration, Takeda will utilize Poseida's biodegradable DNA and RNA nanoparticle delivery technology and other proprietary genetic engineering platforms for the research and development of gene therapies.

Poseida Therapeutics and Takeda Partner to Develop Non-Viral In-Vivo Gene Therapy Programs

MilliporeSigma announced the opening of its second Carlsbad, California-based facility, which doubles production capacity to support commercial and industrial manufacturing of viral vectors. 

MilliporeSigma Completes $110-Million Contract Development Manufacturing Facility for Gene Therapy

Pharmalex has launched the Biopharma Excellence brand, a new service line that combines the expertise of PharmaLex, ERA Consulting, and Biopharma Excellence.

Pharmalex Launches Major New Service Line, Biopharma Excellence

The collaboration between Intellia and SparingVision will work to develop genomic medicines for ocular diseases.

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

The Pharmaceutical Technology and BioPharm International editors host industry experts, highlighting trends and new technologies. 

INTERPHEX Keynote Sessions on the Innovation Stage

AstraZeneca reports that its combination antibody therapy, AZD7442, reduced chances of severe COVID-19 or death by as much as 67%.

AstraZeneca’s AZD7442 Clinical Trial Meets Primary Endpoint